BEIJING (Reuters) - China’s drug safety body has found no problems in its inspection of 45 vaccine makers and will step up supervision of vaccine quality, it said on Friday, following a scandal that put children at risk.
The inspections were done between July 23 and Aug 9, the State Administration for Market Regulation said in a statement.
The statement comes after a public outcry over the discovery that Changsheng Bio-technology Co Ltd falsified data for a rabies vaccine and made an ineffective vaccine for babies. Beijing has promised to punish all those responsible and prevent a recurrence.
Reporting by Beijing Monitoring Desk; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.